Close this search box.

30 Years of Evidence

Join the experts’ corner

This page presents publications and webinars from around the globe. It includes evidence for a wide range of treatment sites including malignant and benign disease, different fractionation schedules and motion synchronization techniques for both the CyberKnife® and TomoTherapy® platforms. We update new papers on a regular basis. Please take a moment to explore the page and see the evidence we have collected to truly demonstrate how we are making a change to peoples’ lives.

Featured Content

ESTRO 2024

SBRT Focal Boost for Localised Prostate Cancer: Primary Outcomes of the SPARC Prospective Trial

Date: 2024
Treatment Technique: SBRT
Platform: CyberKnife System
Author: Binnaz Yasar et al. 
ESTRO 2024

Efficacy and Toxicity of Moderately Hypofractionated Radiotherapy via Helical TomoTherapy versus Conventional Radiotherapy Combined with Concurrent Chemotherapy for Patients with Unresectable

Date: 2024
Treatment Technique: IG-IMRT
Platform: TomoTherapy System
Author: Huang Wenhan et al.
ESTRO 2024

Feasibility of SBRT with CyberKnife in the Scenario of Lung Metastases Re-RT: Monoinstitutional Experience

Date: 2024
Treatment Technique: SBRT
Platform: CyberKnife System
Author: Esmeralda Scipilliti et al.
  • Products

  • Techniques

  • Types

  • Indications

  • Event

  • Formats


Industry-leading service to support your ongoing success, from speedy install and optimization, to proactive monitoring and unrivalled on-site service, to smart upgrade paths to keep your system at the leading edge.

Treatment Solutions

From robotic to helical radiation therapy delivery, we invent unique, market-changing solutions that are designed to deliver radiation treatments across a full spectrum of patient needs.

Treatment Centers

What's New

Your go-to source for staying informed about our advancements.

Why Accuray

Accuray is expanding radiation therapy: our products can deliver it accurately, precisely and effectively, from oncology to neuro-radiosurgery and beyond.